1YSN

Solution structure of the anti-apoptotic protein Bcl-xL complexed with an acyl-sulfonamide-based ligand


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Submitted: 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T.Elmore, S.W.Shoemaker, A.R.Armstrong, R.C.Augeri, D.J.Belli, B.A.Bruncko, M.Deckwerth, T.L.Dinges, J.Hajduk, P.J.Joseph, M.K.Kitada, S.Korsmeyer, S.J.Kunzer, A.R.Letai, A.Li, C.Mitten, M.J.Nettesheim, D.G.Ng, S.Nimmer, P.M.O'Connor, J.M.Oleksijew, A.Petros, A.M.Reed, J.C.Shen, W.Tahir, S.K.Thompson, C.B.Tomaselli, K.J.Wang, B.Wendt, M.D.Zhang, H.Fesik, S.W.Rosenberg, S.H.

(2005) Nature 435: 677-681

  • DOI: 10.1038/nature03579
  • Primary Citation of Related Structures:  
    1YSI, 1YSG, 1YSN, 1YSX, 1YSW

  • PubMed Abstract: 
  • Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-X(L) and Bcl-2, are overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy ...

    Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-X(L) and Bcl-2, are overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy. Bcl-X(L) expression correlates with chemo-resistance of tumour cell lines, and reductions in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival. The development of inhibitors of these proteins as potential anti-cancer therapeutics has been previously explored, but obtaining potent small-molecule inhibitors has proved difficult owing to the necessity of targeting a protein-protein interaction. Here, using nuclear magnetic resonance (NMR)-based screening, parallel synthesis and structure-based design, we have discovered ABT-737, a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumours, and produces cures in a high percentage of the mice.


    Organizational Affiliation

    Idun Pharmaceuticals, 9380 Judicial Drive, San Diego, California 92121, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Apoptosis regulator Bcl-XA181Homo sapiensMutation(s): 0 
Gene Names: BCL2L1BCL2LBCLX
Find proteins for Q07817 (Homo sapiens)
Explore Q07817 
Go to UniProtKB:  Q07817
NIH Common Fund Data Resources
PHAROS  Q07817
Protein Feature View
Expand
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
43B
Query on 43B

Download CCD File 
A
3-NITRO-N-{4-[2-(2-PHENYLETHYL)-1,3-BENZOTHIAZOL-5-YL]BENZOYL}-4-{[2-(PHENYLSULFANYL)ETHYL]AMINO}BENZENESULFONAMIDE
C36 H30 N4 O5 S3
KYLSTDPZEIQYFX-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Submitted: 
  • OLDERADO: 1YSN Olderado

Structure Validation

View Full Validation Report



Entry History 

Revision History 

  • Version 1.0: 2005-06-07
    Type: Initial release
  • Version 1.1: 2007-12-10
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance